Ersodetug Updated Nov 13
The next hard catalyst for ersodetug is the full topline results from the Phase 3 upLIFT study in tumor HI, expected by mid-December 2026. Positive results would support a BLA filing for tumor HI, while the congenital HI path remains uncertain after the sunRIZE miss. For LGND holders, this is a minor portfolio contributor; for RZLT holders, it is the primary value driver.
- The Phase 3 upLIFT study in tumor hyperinsulinism met its primary efficacy endpoint, with 13 of 16 participants achieving the response criterion.
- Ersodetug has both FDA Breakthrough Therapy Designation and Orphan Drug Designation for tumor HI, which could accelerate development and review.
- Through the XOMA acquisition (closed July 2026), Ligand holds high-single to mid-teen percentage royalty rights on any future ersodetug sales.
- The Phase 3 sunRIZE study in congenital hyperinsulinism failed its primary endpoint in December 2025, leaving the regulatory path for that larger indication unresolved.
- Rezolute priced a $100M stock offering concurrently with the positive upLIFT news, diluting existing shareholders.
- Tumor hyperinsulinism is an ultra-rare condition with limited commercial upside; peak sales estimates for ersodetug are only around $300M.